The final agenda is available for September's ADAPT (Accelerating Development and Advancing Personalized Therapy) congress in Washington, D.C.
A quick summary of the tracks:
Track 1: Optimizing Clinical Trials
Track 2: Implementing Personalized Medicine
Track 3: Advancing Cancer Therapy
Track 4: Bridging Silos in Biomarker Development
Featured speakers include FDA Deputy Director Douglas Throckmorton; J. Carl Barrett, VP, Global Head Oncology Translational
Medicine, Novartis; Nicholas C. Dracopoli, VP, Biomarkers, Centocor R&D, Johnson & Johnson; and Giora Feuerstein, AVP, Head,Discovery Translational Medicine, Wyeth Research.
--Paul Thomas
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment